Evaluation of Different Methods for Determining Serum Concentrations of Cardiac Glycosides

  • V. P. ButlerJr.
Conference paper
Part of the International Boehringer Mannheim Symposia book series (BOEHRINGER)


Two centuries have passed since Withering first reported that digitalis “has a power over the motion of the heart, to a degree yet unobserved in any other medicine” (Withering, 1937). Although digitalis glycosides are now widely used in the therapy of congestive heart failure, the dosage of digitalis preparations must, as in Withering’s day, be carefully adjusted to the needs of each individual patient in order that an optimal therapeutic effect may be achieved without the development of toxic side-effects because, as Withering noted, excessive digitalis “occasions sickness, vomiting. purging, giddiness, confused vision, objects appearing green or yellow ... slow pulse ... cold sweats, convulsions, syncope, death” (Withering, 1937). Developments in the first 6 decades of this Century which have enhanced the physician’s ability to adjust digitalis dosages to the specific needs of individual patients have included: the isolation of highly purified cardenolides, the recognition of the effects of digitalis on the electrocardiogram, a better definition of the effects of cardiac glycosides on myocardial contractility, conduction, and automaticity, and an appreciation of the role of electrolyte disturbances in facilitating the development of digitalis toxicity (Butler, 1972).


Cardiac Glycoside Serum Digoxin Concentration Digitalis Glycoside Competitive Protein Binding Tritiated Digoxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beiser, S.M., Butler, V.P., Jr., Erlanger, B.F.: Hapten-protein conjugates: methodology and application. In: Miescher, P.A., Müller-Eberhard, H.J. (eds.): Textbook of Immunopathology, 2nd ed. New York: Grune & Stratton 1976, p. 15Google Scholar
  2. Belz, G.G., Brech, W.J., Kleeberg, U.R., Rudofsky, G., Belz, G.: Characterization and specificity of proscillaridin antibodies. Naunyn Schmiedebergs Arch. Pharmakol. 279,105 (1973)CrossRefGoogle Scholar
  3. Belz, G.G., Stauch, M., Rudofsky, G.: Plasma levels after a single oral dose of proscillaridin. Eur. J. Clin. Pharmacol. 7, 95 (1974 a)PubMedCrossRefGoogle Scholar
  4. Belz, G.G., Rudofsky, G., Lossnitzer, K., Wolf, G., Stauch, M.: Plasmaspiegel und Elektrokardiogramm nach intravenöser Applikation von Proscillaridin und Digoxin. Z. Kardiol. 63, 201 (1974b)PubMedGoogle Scholar
  5. Belz, G.G., Pf lederer, W.: Studies on a plasma cardiac glycoside assay based upon displacement of 3H-ouabain from Na+-K+-ATPase. Basic Res. Cardiol. 70, 142 (1975)PubMedCrossRefGoogle Scholar
  6. Bentley, J.D., Burnett, G.H., Conklin, R.L., Wasserburger, R.H.: Clinical application of serum digitoxin levels. A simplified plasma détermination. Circulation 41, 67 (1970)PubMedGoogle Scholar
  7. Berson, S.A., Yalow, R.S.: Radioimmunoassays of peptide hormones in plasma. N. Engl. J. Med. 277, 640 (1967)PubMedCrossRefGoogle Scholar
  8. Bertler, A., Redfors, A.: An improved method of estimating digoxin in human plasma. Clin. Pharmacol. Ther. 11, 665 (1970)PubMedGoogle Scholar
  9. Bodem, G., Gilfrich, H.J.: Methoden zur Bestimmung von Digoxin und Digitoxin im Blut und ihre klinische Bedeutung. Klin. Wochenschr. 51, 57 (1973)PubMedCrossRefGoogle Scholar
  10. Brooker, G., Jelliffe, R.W.: Serum cardiac glycoside assay based upon displacement of 3H-ouabain from Na-K ATPase. Circulation 45, 20 (1972)PubMedGoogle Scholar
  11. Burnett, G.H., Conklin, R.L.: The enzymatic assay of plasma digoxin. J. Lab. Clin. Med. 78, 779 (1971)PubMedGoogle Scholar
  12. Butler, V.P., Jr.: Digoxin: immunologic approaches to measurement and reversai of toxicity. N. Engl. J. Med. 283,1150 (1970)PubMedCrossRefGoogle Scholar
  13. Butler, V.P., Jr.: Digoxin radioimmunoassay. Lancet 1971/1,186 Butler, V.P., Jr.: Assays of digitalis in the blood. Prog. Cardiovasc. Dis. 14, 571 (1972)PubMedCrossRefGoogle Scholar
  14. Butler, V.P.: Jr., Beiser, S.M.: Antibodies to small molecules: biological and clinical applications. Adv. Immunol. 17, 255 (1973)PubMedCrossRefGoogle Scholar
  15. Butler, V.P., Jr., Chen, J.P.: Digoxin-specific antibodies. Proc. Nat. Acad. Sci. U.S.A. 57, 71 (1967)CrossRefGoogle Scholar
  16. Butler, V.P., Jr., Lindenbaum, J.: Serum digitalis measurements in the assessment of digitalis résistance and sensitivity. Am. J. Med. 58, 460 (1975)PubMedCrossRefGoogle Scholar
  17. Butler, V.P., Jr., Schmidt, D.H., Watson, J.F., Gardner, J.D.: Production and properties of digoxin-specific antibodies. Ann. N.Y. Acad. Sci. 242, 717 (1974)CrossRefGoogle Scholar
  18. Castle, M.C.: Isolation and quantitation of picomole quantities of digoxin, digitoxin and their metabolites by high-pressure liquid chromatography. J. Chromatogr. 115, 437 (1975)PubMedCrossRefGoogle Scholar
  19. Clark, D.R., Kalman, S.M.: Dihydrodigoxin: a common metabolite of digoxin in man. Drug Metab. Dispos.2, 148 (1974)PubMedGoogle Scholar
  20. Doherty, J.E.: The clinical pharmacology of digitalis glycosides: a review. Am. J. Med. Sci. 255, 382 (1968)PubMedCrossRefGoogle Scholar
  21. Doherty, J.E., Perkins, W.H.: Tissue concentration and turnover of tritiated digoxin in dogs. Am. J. Cardiol. 17, 47 (1966)PubMedCrossRefGoogle Scholar
  22. Doherty, J.E., Perkins, W.H., Mitchell, G.K.: Tritiated digoxin studies in human subjects. Arch. Intern. Med. 108, 531 (1961)PubMedGoogle Scholar
  23. Doherty, J.E., Perkins, W.H., Flanigan, W.J.: The distribution and concentration of tritiated digoxin in human tissues. Ann. Intern. Med. 66, 116 (1967)PubMedGoogle Scholar
  24. Duhme, D.W., Greenblatt, D.J., Koch-Weser, J.: Reduction of digoxin toxicity associated with measurement of serum levels. Ann. Intern. Med. 80, 516 (1974)PubMedGoogle Scholar
  25. Ewy, G.A., Kapadia, G.G., Yao, L., Lullin, M., Marcus, F.I.: Digoxin metabolism in the elderly. Circulation 39, 449 (1969)PubMedGoogle Scholar
  26. Grosse-Brockhoff, F., Hausamen, T.-U.: 200 Jahre Herztherapie mit Digitalis: William Withering und das erste Jahrhundert Digitalistherapie. Dtsch. Med. Wochenschr. 100, 1980 (1975)PubMedCrossRefGoogle Scholar
  27. Haasis, R., Larbig, D., Klenk, K.O.: Glykosidkonzentration im Serum und Urin bei Herzgesunden nach Gabe von Beta-Methyl-Digoxin. Klin. Wochenschr. 53, 529 (1975)PubMedCrossRefGoogle Scholar
  28. Härtel, G., Manninen, V., Melin, J., Apajalahti, A.: Serum-digoxin concentrations with a new digoxin derivative, β-methyl-digoxin. Ann. Clin. Res. 5, 87 (1973)PubMedGoogle Scholar
  29. Herbert, V., Lau, K.-S., Gottlieb, C.W., Bleicher, S.J.: Coated charcoal immuno- assay of insulin. J. Clin. Endocrinol. 25, 1375 (1965)CrossRefGoogle Scholar
  30. Huffman, D.H., Crow, J.W., Pentikainen, P., Azarnoff, D.L.: Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am. Heart J. 91, 28 (1976)PubMedCrossRefGoogle Scholar
  31. Kaufman, J.M., Belpaire, F.M.: The influence of metabolites of digoxin and digitoxin on the 86Rb-uptake assay. Eur. J. Clin. Pharmacol. 6, 54 (1973)PubMedCrossRefGoogle Scholar
  32. Lesne, M.: Dosage radioimmunologique de la gitaloxine et de la gitoxine. Arch. Int. Pharmacodyn. Ther. 199, 206 (1972)PubMedGoogle Scholar
  33. Line, W.F., Siegel, S.J., Kwong, A., Frank, C., Ernst, R.: Solid-phase radioimmunoassay for digoxin. Clin. Chem. 19,1361 (1973)PubMedGoogle Scholar
  34. Lowenstein, J.M.: A method for measuring plasma levels of digitalis glycosides. Circulation 31, 228 (1965)PubMedGoogle Scholar
  35. Lowenstein, J.M., Corrill, E.M.: An improved method for measuring plasma and tissue concentrations of digitalis glycosides. J. Lab. Clin. Med. 67, 1048 (1966)PubMedGoogle Scholar
  36. Lukas, D.S.: Some aspects of the distribution and disposition of digitoxin in man. Ann. N.Y. Acad. Sci. 179, 338 (1971)PubMedCrossRefGoogle Scholar
  37. Lukas, D.S., Peterson, R.E.: Double isotope dilution derivative assay of digitoxin in plasma, urine, and stool of patients maintained on the drug. J. Clin. Invest. 45, 782 (1966)PubMedCrossRefGoogle Scholar
  38. Marcus, F.I., Kapadia, G.J., Kapadia, G.G.: The metabolism of digoxin in normal subjects. J. Pharmacol. Exp. Ther. 145, 203 (1964)PubMedGoogle Scholar
  39. Marcus, F.I., Ryan, J.N., Stafford, M.G.: The reactivity of derivatives of digoxin and digitoxin as measured by the Na-K-AtPase displacement assay and by radioimmunoassay. J. Lab. Clin. Med. 85, 610 (1975)PubMedGoogle Scholar
  40. Marks, B.H., Dutta, S., Gauthier, J., Elliott, D.: Distribution in plasma, uptake by the heart and excretion of ouabain-3H in human subjects. J. Pharmacol. Exp. Ther. 145, 351 (1964)PubMedGoogle Scholar
  41. Meade, R.C., Kleist, T.J.: Improved radioimmunoassay of digoxin and other sterol-like Compounds using Somogyi précipitation. J. Lab. Clin. Med. 80, 748 (1972)PubMedGoogle Scholar
  42. Medzihradsky, F., Nandhasri, P.S., Khanna, U.: Enzymatic détermination of cardiac glycosides. Biochem. Med. 5, 285 (1971)CrossRefGoogle Scholar
  43. Nachtmann, F., Spitzy, H., Frei, R.W.: Rapid and sensitive high-resolution procedure for digitalis glycoside analysis by derivatization liquid chromatography. J. Chromatogr. 122, 293 (1976)PubMedCrossRefGoogle Scholar
  44. Okita, G.T., Kelsey, F.E., Talso, P.J., Smith, L.B., Geiling, E.M.K.: Studies of the renal excretion of radioactive digitoxin in human subjects with congestive failure. Circulation 7, 161 (1953)PubMedGoogle Scholar
  45. Oliver, G.C., Jr., Parker, B.M., Brasfield, D.L., Parker, C.W.: The measurement of digitoxin in human serum by radioimmunoassay. J. Clin. Invest. 47, 1035 (1968)PubMedCrossRefGoogle Scholar
  46. Rosenthal, A.F., Vargas, M.G., Klass, C.S.: Evaluation of enzymemultiplied immunoassay technique (EMIT) for determination of serum digoxin. Clin. Chem, 22, 1899 (1976)PubMedGoogle Scholar
  47. Schwartz, A., Matsui, H., Laughter, A.H.: Tritiated digoxin binding to (Na+ + K+)-activated adenosine triphosphatase: possible allosteric site. Science 160, 323 (1968)PubMedCrossRefGoogle Scholar
  48. Seiden, R., Smith, T.W.: Ouabain pharmacokinetics in dog and man: détermination by radioimmunoassay. Circulation 45,1176 (1972)Google Scholar
  49. Seiden, R., Klein, M.D., Smith, T.W.: Plasma concentration and urinary excrétion kinetics of acetyl strophanthidin. Circulation 47, 744 (1973)Google Scholar
  50. Shatzmann, H.J.: Herzglykoside als Hemmstoff für den aktiven Kalium- and Natriumtransport durch die Erythrocytenmembran. Helv. Physiol. Pharmacol. Acta 11, 346 (1953)Google Scholar
  51. Skou, J.C.: Enzymatic basis for the active transport of Na+ and K+ across cell membrane. Physiol. Rev. 45, 596 (1965)PubMedGoogle Scholar
  52. Smith, T.W.: Radioimmunoassay for serum digitoxin concentration: methodology and clinical experience. J. Pharmacol. Exp. Ther. 175, 352 (1970)PubMedGoogle Scholar
  53. Smith, T.W.: Contribution of quantitative assay technics to the understanding of the clinical pharmacology of digitalis. Circulation 46,188 (1972)PubMedGoogle Scholar
  54. Smith, T.W.: Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. Am. J. Med. 58, 470 (1975)PubMedCrossRefGoogle Scholar
  55. Smith, T.W., Haber, E.: Current techniques for serum or plasma digitalis assay and their potential clinical application. Am. J. Med. Sci. 259, 301 (1970)PubMedCrossRefGoogle Scholar
  56. Smith, T.W., Haber, E.: Clinical value of the radioimmunoassay of the digitalis glycosides. Pharmacol. Rev. 25, 219 (1973)PubMedGoogle Scholar
  57. Smith, T.W., Skubitz, K.M.: Kinetics of interactions between antibodies and haptens. Biochemistry 14, 1496 (1975)PubMedCrossRefGoogle Scholar
  58. Smith, T.W., Butler, V.P., Jr., Haber, E.: Determination of therapeutic and toxic serum digoxin conentrations by radioimmunoassay. N. Engl. J. Med. 281, 1212 (1969)PubMedCrossRefGoogle Scholar
  59. Smith, T.W., Butler, V.P., Jr., Haber, E.: Characterization of antibodies of high affinity and specificity for the digitalis glycoside digoxin. Biochemistry 9, 331 (1970)PubMedCrossRefGoogle Scholar
  60. Watson, E., Kalman, S.M.: Assay of digoxin in plasma by gas chromatography. J. Chromatogr. 56, 209 (1971)PubMedCrossRefGoogle Scholar
  61. Watson, E., Tramell, P., Kalman, S.M.: Identification of submicrogram amounts of digoxin, digitoxin and their metabolic products: isolation by chromatography and preparation of derivatives for assay by electron capture detector. J. Chromatogr. 69,157 (1972)PubMedCrossRefGoogle Scholar
  62. Watson, E., Clark, D.R., Kalman, S.M.: Identification by gas chromatography-mass spectroscopy of dihydrodigoxin-a metabolite of digoxin in man. J. Pharmacol. Exp. Therap. 184, 424 (1973)Google Scholar
  63. Withering, W.: An account of the Foxglove and some of its medical uses: with practical remarks on dropsy and other diseases. Birmingham England, M. Swinney, 1785. Reprinted in Med. Classics 2, 295 (1937)Google Scholar
  64. Withering, W.: Letter to Hall Jackson, 1786. Cited by Caroll, D.: Introduction of digitalis into North America. N. Engl. J. Med. 235, 808 (1946)CrossRefGoogle Scholar
  65. Yalow, R.S., Berson, S.A.: Immunoassay of plasma insulin. Methods Biochem. Anal. 12, 69 (1964)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • V. P. ButlerJr.

There are no affiliations available

Personalised recommendations